ClinicalTrials.gg
CompletedNCT03374306Updated Oct 16, 2024Results posted

Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate

An interventional study of Atropine (0.01%) and Artificial tear in Myopia, sponsored by The Hong Kong Polytechnic University. Completed at 1 site in Hong Kong. Open to participants aged 7 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by The Hong Kong Polytechnic University · Not applicable, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Randomized
Ages
7 Years to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
37th of 54
71 · median 144
Started
2018
with 6 others
No phase
13 of 54
6 open now
Registered
10th of 54
by date
Lead sponsor
2 of 54
The Hong Kong Polytechnic University

Among the 54 studies testing atropine in Myopia, this one is the 37th largest by enrollment, is one of 7 that started in 2018, is one of 13 with no phase, and was the 10th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 7 Years to 10 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

Our project is a 24-month longitudinal randomized controlled trial that aims to investigate the myopia development after topical application of 0.01% atropine in children with either fast or slow myopia progression classified according to their initial electro-retinal responses. This will help elucidate the effectiveness of using low concentration atropine for myopia control in children with different myopia progression rates.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Myopia
  • Myopia control
  • Atropine
  • Electroretinogram
  • Multifocal Electroretinogram
04

Who can participate

Ages eligible
7 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Age between 7 and 10 years
  • Good general health and no family history of ocular diseases
  • No current or history of epilepsy or asthma
  • Myopia : -0.50 to -1.00 D (inclusive, both eyes)
  • Astigmatism : ≤ 0.50 D
  • No hyperopia, amblyopia or strabismus
  • No reported ocular eye diseases or disorders
  • No drug allergy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    Atropine 0.01%

    Group receiving atropine treatment for 18 months

    Drug: Atropine (0.01%)

  • Placebo comparator
    Artifical tear

    Group receiving placebo for 18 months

    Drug: Artificial tear

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Changes in Refractive Error (SER)

    Annualized changes in refractive error (SER) after receiving the 0.01 atropine or artificial tears up to 18 months

    Time frame: 18 months

Secondary outcomes

  1. Annualized Change in Axial Length

    Annualized change in axial length after receiving the 0.01 atropine or artificial tears up to 18 months

    Time frame: 18 months

07

Results

Posted Oct 16, 2024

Participant flow

Recruitment period: Feb 2018 - Oct 2018 Location: HK PolyU Optometry clinic

Participant flow — Overall Study
MilestoneAtropine 0.01%Artifical Tear
Started3635
Completed3427
Not completed28

Outcome measures

PrimaryAnnualized Changes in Refractive Error (SER)

Annualized changes in refractive error (SER) after receiving the 0.01 atropine or artificial tears up to 18 months

Time frame:
18 months
Reported as:
Mean · Dioptre/year
Annualized Changes in Refractive Error (SER)
Dioptre/yearAtropine 0.01%Artifical Tear
Annualized Changes in Refractive Error (SER)-0.70 ± 0.39-0.66 ± 0.41
SecondaryAnnualized Change in Axial Length

Annualized change in axial length after receiving the 0.01 atropine or artificial tears up to 18 months

Time frame:
18 months
Reported as:
Mean · mm/year
Annualized Change in Axial Length
mm/yearAtropine 0.01%Artifical Tear
Annualized Change in Axial Length0.3 ± 0.220.32 ± 0.16

Adverse events

Collected over 18 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atropine 0.01%0/34 (0%)0/34 (0%)0/34 (0%)
Artifical Tear0/27 (0%)0/27 (0%)0/27 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Atropine 0.01%Artifical TearTotal
<=18 years342761
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Atropine 0.01%Artifical TearTotal
Female171330
Male171431
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Atropine 0.01%Artifical TearTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Atropine 0.01%Artifical TearTotal
Hong Kong342761
Refractive errors
Refractive errors(Dioptre)Atropine 0.01%Artifical TearTotal
Mean-1.88 ± 1.08-1.74 ± 0.71-1.8 ± 0.95
Electroretinogram
Electroretinogram(nV/deg^2)Atropine 0.01%Artifical TearTotal
Mean41.65 ± 24.450.01 ± 27.7545.16 ± 25.45
Axial length
Axial length(mm)Atropine 0.01%Artifical TearTotal
Mean24.17 ± 0.7924.09 ± 0.7424.13 ± 0.76
08

Study locations

1 site
  • School of Optometry, Hong Kong Polytechnic University
    Hong Kong, 00000, Hong Kong
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2018 to primary completion in Dec 2019, 22 months.

Results were first posted in Oct 2024, 4 years 9 months after primary completion.

Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 22 months is below that.

Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2017
First posted
Dec 15, 2017
StartActual
Feb 1, 2018
Primary completionActual
Dec 31, 2019
CompletionActual
Aug 31, 2020
Results first posted
Oct 16, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03374306
Responsible party
Henry HL Chan, PhD (Association Professor, The Hong Kong Polytechnic University) — Principal investigator
First posted
Dec 15, 2017
Start date
Feb 1, 2018
Primary completion
Dec 31, 2019
Completion
Aug 31, 2020
Results posted
Oct 16, 2024
Last update
Oct 16, 2024

Study contacts

Henry HL CHAN, PhD
principal investigator · The Hong Kong Polytechnic University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion